Table 2 Results of subgroup analysis
Outcome | Subgroup | Number of trials | Number of participants | RR (95% CI) | Phetero | |
|---|---|---|---|---|---|---|
AF | Overall | 21 | 51,193 | 0.82 (0.70–0.96) |  | |
Baseline condition | DM | 16 | 44,896 | 0.84 (0.71–1.00) | 0.63 | |
CKD | 3 | 1474 | 0.93 (0.18–4.68) | |||
HF | 2 | 4823 | 0.65 (0.40–1.07) | |||
ASCVD | No ASCVD | 18 | 43,114 | 0.79 (0.67–0.94) | 0.16 | |
ASCVD present | 3 | 8079 | 1.23 (0.69–2.19) | |||
SGLT2i agent | Canagliflozin | 6 | 16,378 | 0.90 (0.65–1.26) | 0.39 | |
Dapagliflozin | 7 | 25,090 | 0.75 (0.61–0.91) | |||
Empagliflozin | 7 | 9258 | 1.19 (0.68–2.08) | |||
Ertugliflozin | 1 | 467 | 1.48 (0.06–36.08) | |||
Follow-up duration |  ≤ 1 year | 11 | 4916 | 0.82 (0.69–0.97) | 0.90 | |
 > 1 year | 10 | 42,677 | 0.82 (0.70–0.96) | |||
Embolic stroke | Overall | 6 | 44,205 | 0.32 (0.12–0.85) |  | |
Baseline condition | DM | 4 | 38,723 | 0.32 (0.10–1.03) | 0.99 | |
CKD | 1 | 4401 | 0.25 (0.01–6.21) | |||
HF | 1 | 4744 | 0.25 (0.03–3.20) | |||
ASCVD | No ASCVD | 5 | 37,185 | 0.37 (0.12–1.10) | 0.53 | |
ASCVD present | 1 | 7020 | 0.17 (0.02–1.59) | |||
SGLT2i agent | Canagliflozin | 2 | 14,543 | 0.29 (0.03–2.77) | 0.78 | |
Dapagliflozin | 3 | 21,904 | 0.43 (0.11–1.68) | |||
Empagliflozin | 4 | 7758 | 1.19 (0.03–1.21) | |||
Follow-up duration |  ≤ 1 year | 1 | 738 | 0.25 (0.01–6.21) | 0.89 | |
 > 1 year | 5 | 43,467 | 0.32 (0.12–0.92) | |||
AFL | Overall | 9 | 45,478 | 0.83 (0.58–1.17) |  | |
Baseline condition | DM | 6 | 36,333 | 0.75 (0.52–1.09) | 0.19 | |
CKD | 1 | 4401 | 1.00 (0.14–7.08) | |||
HF | 1 | 4744 | 2.66 (0.71–10.03) | |||
ASCVD | No ASCVD | 6 | 37,439 | 0.91 (0.55–1.48) | 0.90 | |
ASCVD present | 3 | 8039 | 0.97 (0.36–2.66) | |||
SGLT2i agent | Canagliflozin | 2 | 14,543 | 1.08 (0.56–2.10) | 0.95 | |
Dapagliflozin | 3 | 22,826 | 0.91 (0.28–3.00) | |||
Empagliflozin | 4 | 8109 | 1.14 (0.45–3.03) | |||
Follow-up duration |  ≤ 1 year | 2 | 1019 | 0.33 (0.01–8.20) | 0.56 | |
 > 1 year | 7 | 44,459 | 0.87 (0.59–1.29) | |||
AF/AFL | Overall | 22 | 49,115 | 0.82 (0.71–0.95) |  | |
Baseline condition | DM | 17 | 41,686 | 0.82 (0.70–0.97) | 0.99 | |
CKD | 3 | 5606 | 0.83 (0.46–1.51) | |||
HF | 2 | 4823 | 0.79 (0.51–1.24) | |||
ASCVD | No ASCVD | 18 | 40,114 | 0.79 (0.68–0.93) | 0.16 | |
ASCVD present | 4 | 9001 | 1.16 (0.70–1.91) | |||
SGLT2i agent | Canagliflozin | 6 | 16,378 | 0.94 (0.70–1.26) | 0.20 | |
Dapagliflozin | 8 | 26,012 | 0.74 (0.62–0.89) | |||
Empagliflozin | 7 | 9258 | 1.21 (0.74–1.97) | |||
Ertugliflozin | 1 | 467 | 1.48 (0.06–36.08) | |||
Follow-up duration |  ≤ 1 year | 12 | 5838 | 0.73 (0.31–1.71) | 0.78 | |
 > 1 year | 10 | 42,677 | 0.82 (0.71–0.96) | |||
VT | Overall | 7 | 43,963 | 0.73 (0.53–0.99) |  | |
Baseline condition | DM | 4 | 34,739 | 0.90 (0.56–1.42) | 0.50 | |
CKD | 1 | 2501 | 0.50 (0.05–5.50) | |||
HF | 2 | 4823 | 0.62 (0.41–0.95) | |||
ASCVD | No ASCVD | 6 | 36,846 | 0.77 (0.56–1.06) | 0.30 | |
ASCVD present | 2 | 7117 | 0.44 (0.16–1.20) | |||
SGLT2i agent | Canagliflozin | 2 | 14,543 | 0.80 (0.28–2.32) | 0.48 | |
Dapagliflozin | 3 | 22,224 | 0.82 (0.50–1.33) | |||
Empagliflozin | 3 | 7196 | 0.42 (0.16–1.11) | |||
Follow-up duration |  ≤ 1 year | 3 | 496 | 0.98 (0.10–9.29) | 0.79 | |
 > 1 year | 5 | 43,647 | 0.72 (0.53–0.99) | |||
Cardiac arrest | Overall | 7 | 44,751 | 0.83 (0.61–1.14) |  | |
Baseline condition | DM | 4 | 34,868 | 0.74 (0.42–1.30) | 0.93 | |
CKD | 2 | 5139 | 0.72 (0.25–2.08) | |||
HF | 1 | 4744 | 0.90 (0.37–2.21) | |||
ASCVD | No ASCVD | 6 | 37,731 | 0.92 (0.66–1.30) | 0.12 | |
ASCVD present | 1 | 7020 | 0.46 (0.20–1.03) | |||
SGLT2i agent | Canagliflozin | 2 | 14,543 | 0.85 (0.46–1.52) | 0.44 | |
Dapagliflozin | 3 | 22,450 | 0.88 (0.44–1.75) | |||
Empagliflozin | 2 | 7758 | 0.48 (0.22–1.04) | |||
Follow-up duration |  ≤ 1 year | 1 | 738 | 0.76 (0.05–12.13) | 0.97 | |
 > 1 year | 6 | 44,013 | 0.81 (0.56–1.16) | |||